As of 2025-10-23, the Intrinsic Value of GT Biopharma Inc (GTBP) is -34.68 USD. This GTBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.67 USD, the upside of GT Biopharma Inc is -5,271.39%.
Based on its market price of 0.67 USD and our intrinsic valuation, GT Biopharma Inc (GTBP) is overvalued by 5,271.39%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -34.68 - -34.68 | -34.68 | -5,271.39% |
| P/E | (109.77) - (164.65) | (137.21) | -20558.0% |
| DDM - Stable | (20.76) - (80.29) | (50.53) | -7633.3% |
| DDM - Multi | (20.35) - (64.82) | (31.40) | -4781.2% |
| Market Cap (mil) | 2.39 |
| Beta | 0.06 |
| Outstanding shares (mil) | 3.56 |
| Enterprise Value (mil) | 2.39 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.37% |
| Cost of Debt | 5.00% |
| WACC | 7.52% |